BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 20
• 21
• 22
• 23
• 24
• 27
• 28
• 29
• 30

• Business

  Palatin Technologies to Report Fiscal Year 2010 Fourth Quarter Results; Teleconference and Webcast to be held on September 27, 2010

  September 22, 2010

   · 

  1 min read
• Pharm Country

  Neuro Kinetics, Inc. to Showcase Enhanced Control & Analysis Software at Otolaryngology Conference

  September 22, 2010

   · 

  2 min read
• Bio NC

  nContact Surgical, Inc.: Interdisciplinary Convergent Approach May Represent Future for Treatment of Atrial Fibrillation

  September 22, 2010

   · 

  3 min read
• Policy

  Gen-Probe Incorporated Files US Regulatory Application for PROGENSA(R) PCA3 Assay, New Molecular Test to Help Determine Need for Repeat Prostate Biopsies

  September 22, 2010

   · 

  5 min read
• Pharm Country

  Maquet Cardiovascular LLC Announces Enrollment of First Patient in Study Evaluating Best-Practice Endoscopic Vein Harvesting in Coronary Artery Bypass Surgery

  September 22, 2010

   · 

  5 min read
• Policy

  Volcano Corporation Reacts Positively to the New European PCI Guidelines That Raise FFR-Guided PCI to a Class I, Level of Evidence a Recommendation

  September 22, 2010

   · 

  5 min read
• BioMidwest

  Procter & Gamble Partners With Target to Raise Money and Awareness for Breast Cancer Early Detection Planning

  September 22, 2010

   · 

  2 min read
• Valeant Pharmaceuticals International and Biovail Pharmaceuticals, Inc. Announce Valeant’s Intention to Declare a Special Dividend to Stockholders Upon Obtaining Shareholder Approval, Financing and Satisfaction of Other Closing Conditions

  September 22, 2010

   · 

  8 min read
• Drug Development

  Novartis AG Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing’s Disease, a Debilitating Hormonal Disorder

  September 22, 2010

   · 

  11 min read
• Biotech Beach

  Marshall Edwards, Inc. CEO to Present at JMP Securities Healthcare Conference

  September 22, 2010

   · 

  1 min read